Kirk R. Gustafson, Ph.D.

Senior Scientist

Molecular Targets Laboratory

NCI/CCR

Building 562, Room 201
Frederick, MD 21702-1201

301-846-5197

gustafki@mail.nih.gov

Research Topics

The NCI maintains a repository of natural product extracts that is the largest and most diverse in the world. These extracts, derived from terrestrial, marine and microbial organisms, constitute a unique source of chemical diversity for the discovery of compounds that can interact with specific molecular targets associated with human cancer. We are utilizing high throughput screening technologies to help identify compounds and extracts that can specifically interact with or modulate the function of selected biochemical targets or processes. Bioassay-guided chemical fractionation of natural products extracts is employed to isolate and purify the individual bioactive compounds. Identification and structural characterization of these compounds provides new structural classes or molecular scaffolds for the development of potential drug leads or biological probes which can interact with the desired molecular target. In addition to extensive spectroscopic analyses, our efforts include rigorous evaluation of a new compound's potency, molecular target specificity, and mode of action.

Biography

Dr. Gustafson earned his Ph.D. in organic chemistry from the University of British Columbia in 1984 under the direction of Professor Raymond J. Andersen. From 1984 to 1987 he worked as a postdoctoral fellow with Professor William Fenical at the Scripps Institution of Oceanography. He has a longstanding interest in the isolation, structural determination, and biological characterization of new secondary metabolites produced by terrestrial plants, marine organisms, and microbial isolates. Dr. Gustafson joined the NCI in 1987 and his studies have focused on utilizing the inherent chemical diversity found in natural product sources to help discover new compounds which can serve as biochemical probes or drug leads relevant to cancer and other human diseases.

Selected Publications

  1. Blees JS, Bokesch HR, Rübsamen D, Schulz K, Milke L, Bajer MM, Gustafson KR, Henrich CJ, McMahon JB, Colburn NH, Schmid T, Brüne B. Erioflorin stabilizes the tumor suppressor Pdcd4 by inhibiting its interaction with the E3-ligase β-TrCP1. PLoS One. 2012;7(10):e46567.

  2. Diyabalanage T, Ratnayake R, Wilson JA, Henrich CJ, Beutler JA, Colburn NH, McMahon JB, Gustafson KR. Nothospondin, a new AP-1 inhibitory quassinoid from the Cameroonian plant Nothospondias staudtii. Bioorg Med Chem Lett. 2011;21(15):4397-9.

  3. Versiani MA, Diyabalanage T, Ratnayake R, Henrich CJ, Bates SE, McMahon JB, Gustafson KR. Flavonoids from eight tropical plant species that inhibit the multidrug resistance transporter ABCG2. J Nat Prod. 2011;74(2):262-6.

  4. Oku N, Takada K, Fuller RW, Wilson JA, Peach ML, Pannell LK, McMahon JB, Gustafson KR. Isolation, structural elucidation, and absolute stereochemistry of enigmazole A, a cytotoxic phosphomacrolide from the Papua New Guinea marine sponge Cinachyrella enigmatica. J Am Chem Soc. 2010;132(30):10278-85.

  5. Grkovic T, Blees JS, Colburn NH, Schmid T, Thomas CL, Henrich CJ, McMahon JB, Gustafson KR. Cryptocaryols A-H, α-pyrone-containing 1,3-polyols from Cryptocarya sp. implicated in stabilizing the tumor suppressor Pdcd4. J Nat Prod. 2011;74(5):1015-20.


This page was last updated on October 5th, 2017